Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.

Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009 Dec; 100(12):2411-8.

View in: PubMed

collapse authors with profiles